Adicet Bio, Inc. (ACET) is a Biotechnology company in the Healthcare sector, currently trading at $7.00. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ACET = $18 (+157.1% upside).
Valuation: ACET trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Net income is $117M (loss), growing at -31.6%/yr. Net profit margin is 0% (thin). Gross margin is 80% (+0 pp trend).
Balance sheet: total debt is $15M against $159M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 7.47 (strong liquidity). Debt-to-assets is 7.7%. Total assets: $192M.
Analyst outlook: 9 / 12 analysts rate ACET as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 85/100 (Pass), Income ?/100 (Fail).
